Fingerprick blood samples to measure serum natalizumab concentrations.
Multiple sclerosis
capillary
extended interval dosing
fingerprick
natalizumab
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
pubmed:
1
12
2022
medline:
3
3
2023
entrez:
30
11
2022
Statut:
ppublish
Résumé
Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood. In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab. Natalizumab concentrations were similar with a mean bias of -0.36 μg/mL (95% CI: 1.3 to -2 μg/mL). This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing.
Sections du résumé
BACKGROUND
UNASSIGNED
Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis.
OBJECTIVE
UNASSIGNED
In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off, it would be preferable to measure natalizumab drug concentrations in capillary blood.
METHODS
UNASSIGNED
In this cross-sectional study in patients treated with intravenous (IV) natalizumab, capillary blood samples by fingerprick and venous blood samples were collected in 30 participants prior to IV administration of natalizumab.
RESULTS
UNASSIGNED
Natalizumab concentrations were similar with a mean bias of -0.36 μg/mL (95% CI: 1.3 to -2 μg/mL).
CONCLUSIONS
UNASSIGNED
This study shows that physicians can monitor natalizumab drug concentrations by a fingerprick, which could be used for personalized extended dosing.
Identifiants
pubmed: 36448735
doi: 10.1177/13524585221136448
pmc: PMC9972227
doi:
Substances chimiques
Natalizumab
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-460Références
Neurol Neuroimmunol Neuroinflamm. 2020 Feb 4;7(2):
pubmed: 32019876
Br J Clin Pharmacol. 2019 Jul;85(7):1544-1551
pubmed: 30927375
Lancet Rheumatol. 2022 May;4(5):e338-e350
pubmed: 35317410
Mult Scler. 2021 Dec;27(14):2240-2253
pubmed: 33821693
Neurology. 2020 Aug 11;95(6):e745-e754
pubmed: 32690785
Neurology. 2019 Oct 8;93(15):e1452-e1462
pubmed: 31515290
Br J Clin Pharmacol. 2017 Nov;83(11):2474-2484
pubmed: 28791718
Mult Scler. 2022 Nov;28(13):2001-2009
pubmed: 34949134
Neurodegener Dis Manag. 2022 Jun;12(3):109-116
pubmed: 35446149
Anal Biochem. 2011 Apr 15;411(2):271-6
pubmed: 21216215